Tetra Bio-Pharma Inc. (TBP.TO) Research

Headquartered in Orléans, Canada, Tetra Bio-Pharma Inc. is a biopharmaceutical company focused on discovering and developing cannabinoid-based medications. Their efforts span several therapeutic areas, including inflammation, pain management, ophthalmology, and oncology. The company's pipeline features various drug candidates: PLENITUDE is being developed for cancer-related pain in advanced patients, while REBORN addresses breakthrough cancer pain. Reduvo is designed to combat chemotherapy-induced nausea and vomiting. ARDS-003 targets sepsis and the prevention of acute respiratory distress syndrome, and SERENITY aims to treat cancer cachexia. Furthermore, Tetra Bio-Pharma is advancing PPP003 for painful dry eye and uveitis pain, and HCC011 for hepatocellular carcinoma.

Market snapshot

Symbol
TBP.TO
Price
$0.03
Day change
0.00%
Market cap
$10.6M
P/E ratio
-0.21x
52-week range
0.015-0.075
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Aleafia Health Inc. (AH.TO)
  • Cloud DX Inc. (CDX.V)
  • CanaFarma Hemp Products Corp. (CNFA.CN)
  • Core One Labs Inc. (COOL.CN)
  • CloudMD Software & Services Inc. (DOC.V)
  • IMV Inc. (IMV.TO)
  • Khiron Life Sciences Corp. (KHRN.V)
  • Mind Cure Health Inc. (MCUR.CN)

Open Tetra Bio-Pharma Inc. (TBP.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.